Home›Screener›TARS›Profile
D
44/100

Tarsus Pharmaceuticals, Inc.

TARSBiotech / Pharma
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-06-17

Tarsus Pharmaceuticals, Inc. (TARS) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 2[1].

TARS has 6 Form 4 insider filings recorded at the SEC in the past 30 days[3].

Sources

  1. ClinicalTrials.gov (2026-06-17) ↗
  2. ClinicalTrials.gov (2026-06-17) ↗
  3. SEC EDGAR · 0001819790 (2026-06-17) ↗
🔬
Clinical Trials
2
NCT07443202Ocular Rosacea
Source ↗
clinicaltrials_gov · Retrieved 2026-06-17
NCT07562087Lyme Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-06-17
👤
Insider Activity
1
6 filings
Source ↗
sec_edgar · Retrieved 2026-06-17
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-15
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials2
Sector Peers (Biotech / Pharma)
ADILAdial Pharmaceuticals, Inc
A
HAOHaoxi Health Technology Limited Class A
A
PBMPsyence Biomedical Ltd. Common Shares
A
IMAImageneBio, Inc.
A
MAIAMAIA Biotechnology, Inc.
A
Data Provenance
cik1 verified
clinical trial2 verified
insider buy1 verified
trial count2 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR